Endocrine Abstracts

Non-alcoholic fatty liver disease is a condition characterised by deposition of fat within the liver and can be associated with progressive inflammation and fibrosis (NASH). Up to 30% of the population may have NAFLD and yet only a small proportion will have progressive disease. This means that accurate stratification of at risk patients is required to ensure best use of NHS resource. The talk will describe the diagnostic modalities that can be used to identify patients including algorithms and imaging modalities. Weight loss has been shown to be effective in reducing steatosis and inflammation, although challenges remain with maintaining weight loss. There are no licensed pharmacotherapies for NAFLD but there is a burgeoning trial portfolio globally and also in the UK which promises the offer of new therapies soon. The talk will focus on current treatment modalities being explored.